Keywords: rituxan, meets, primary, endpoint, ms, trial, usa-based

Rituxan meets primary endpoint in MS trial

Article | 04 September 2006

Print This

USA-based firms Genentech and Biogen Idec say that a study of the co-marketed therapeutic antibody Rituxan (rituximab), used in the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in